Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2024  > 
, , , et alGuidelines for clinical diagnosis and treatment of nontuberculous mycobacterial disease in kidney transplant recipients[J]. ORGAN TRANSPLANTATION. doi: 10.3969/j.issn.1674-7445.2024142
Citation: , , , et alGuidelines for clinical diagnosis and treatment of nontuberculous mycobacterial disease in kidney transplant recipients[J]. ORGAN TRANSPLANTATION. doi: 10.3969/j.issn.1674-7445.2024142
shu

Guidelines for clinical diagnosis and treatment of nontuberculous mycobacterial disease in kidney transplant recipients

doi: 10.3969/j.issn.1674-7445.2024142
  • 1.

    Guangdong Provincial People's Hospital, Guangzhou 510080, China

More Information
  • Corresponding author: Sun Qiquan, Email: sunqiquan@gdph.org.cn
  • Received Date: 2024-05-07
    Available Online: 2024-06-07
    Abstract
  • In recent years, the infection of nontuberculous mycobacterium (NTM) has been increasing rapidly, which captivates widespread attention. The infection rate of NTM in kidney transplant recipients is more significantly elevated due to the impact of immunosuppressive drugs and other factors. However, due to the lack of sufficient research evidence, relevant guidelines for the diagnosis and treatment of NTM after kidney transplantation are still lacking. To further standardize the diagnosis and treatment of NTM disease in kidney transplant recipients, and deepen medical practitioners' understanding and diagnosis and treatment of NTM disease in organ transplantation in China, Branch of Organ Transplantation of Chinese Medical Association organized relevant experts to formulate this guideline by referring to the latest edition of “An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases”, “Expert Consensus on the Diagnosis and Treatment of Nontuberculous Mycobacterial Disease”, and “Technical Specification for Clinical Diagnosis and Treatment of Nontuberculous Mycobacteria in Organ Transplant Recipients (2019 Edition) ”, and considering the characteristics of kidney transplant recipients.

     

    • FullText(HTML)
  • loading
    • References(47)
  • [1]
    DALEY CL, IACCARINO JM, LANGE C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline[J]. Eur Respir J, 2020, 56(1): 2000535. DOI: 10.1183/13993003.00535-2020.
    [2]
    HAWORTH CS, BANKS J, CAPSTICK T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)[J]. Thorax, 2017, 72(Suppl 2): ii1-ii64. DOI: 10.1136/thoraxjnl-2017-210927.
    [3]
    GRIFFITH DE, AKSAMIT T, BROWN-ELLIOTT BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases[J]. Am J Respir Crit Care Med, 2007, 175(4): 367-416. DOI: 10.1164/rccm.200604-571ST.
    [4]
    中华医学会结核病学分会, 《中华结核和呼吸杂志》编辑委员会. 非结核分枝杆菌病诊断与治疗专家共识[J]. 中华结核和呼吸杂志, 2012, 35(8): 572-580. DOI: 10.3760/cma.j.issn.1001-0939.2012.08.006.

    Branch of Tuberculosis of Chinese Medical Association, Editorial Committee of the Chinese Journal of Tuberculosis and Respiratory Diseases. Expert consensus on the diagnosis and treatment of non tuberculosis mycobacterial disease[J]. Chin J Tuberc Respir Dis, 2012, 35(8): 572-580. DOI: 10.3760/cma.j.issn.1001-0939.2012.08.006.
    [5]
    中华医学会器官移植学分会. 器官移植受者非结核分枝杆菌病临床诊疗技术规范(2019版)[J]. 器官移植, 2019, 10(4): 364-368. DOI: 10.3969/j.issn.1674-7445.2019.04.004.

    Branch of Organ Transplantation of Chinese Medical Association. Technical specification for clinical diagnosis and treatment of nontuberculosis mycobacteria in organ transplant recipients (2019 edition)[J]. Organ Transplant, 2019, 10(4): 364-368. DOI: 10.3969/j.issn.1674-7445.2019.04.004.
    [6]
    唐神结, 高文. 临床结核病学[M]. 2版. 北京: 人民卫生出版社, 2019: 1026.
    [7]
    FURUUCHI K, MORIMOTO K, YOSHIYAMA T, et al. Interrelational changes in the epidemiology and clinical features of nontuberculous mycobacterial pulmonary disease and tuberculosis in a referral hospital in Japan[J]. Respir Med, 2019, 152: 74-80. DOI: 10.1016/j.rmed.2019.05.001.
    [8]
    PREVOTS DR, MARRAS TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review[J]. Clin Chest Med, 2015, 36(1): 13-34. DOI: 10.1016/j.ccm.2014.10.002.
    [9]
    MEJIA-CHEW C, CARVER PL, RUTJANAWECH S, et al. Risk factors for nontuberculous mycobacteria infections in solid organ transplant recipients: a multinational case-control study[J]. Clin Infect Dis, 2023, 76(3): e995-e1003. DOI: 10.1093/cid/ciac608.
    [10]
    WINTHROP KL, MARRAS TK, ADJEMIAN J, et al. Incidence and prevalence of nontuberculous mycobacterial lung disease in a large U. S. managed care health plan, 2008-2015[J]. Ann Am Thorac Soc, 2020, 17(2): 178-185. DOI: 10.1513/AnnalsATS.201804-236OC.
    [11]
    ADJEMIAN J, OLIVIER KN, SEITZ AE, et al. Prevalence of nontuberculous mycobacterial lung disease in U. S. Medicare beneficiaries[J]. Am J Respir Crit Care Med, 2012, 185(8): 881-886. DOI: 10.1164/rccm.201111-2016OC.
    [12]
    WU J, ZHANG Y, LI J, et al. Increase in nontuberculous mycobacteria isolated in Shanghai, China: results from a population-based study[J]. PLoS One, 2014, 9(10): e109736. DOI: 10.1371/journal.pone.0109736.
    [13]
    张洁, 苏建荣, 丁北川, 等. 北京地区非结核分枝杆菌菌种分布及耐药性研究[J]. 中华结核和呼吸杂志, 2017, 40(3): 210-214. DOI: 10.3760/cma.j.issn.1001-0939.2017.03.013.

    ZHANG J, SU JR, DING BC, et al. Distribution and drug resistance of nontuberculous Mycobacteria in Beijing[J]. Chin J Tuberc Respir Dis, 2017, 40(3): 210-214. DOI: 10.3760/cma.j.issn.1001-0939.2017.03.013.
    [14]
    洪创跃, 李金莉, 赵广录, 等. 2013—2017年深圳市非结核分枝杆菌流行状况分析[J]. 中国防痨杂志, 2019, 41(5): 529-533. DOI: 10.3969/j.issn.1000-6621.2019.05.011.

    HONG CY, LI JL, ZHAO GL, et al. Analysis of epidemic characteristics of non-tuberculous mycobacterium strains in Shenzhen between 2013-2017[J]. Chin J Antituberc, 2019, 41(5): 529-533. DOI: 10.3969/j.issn.1000-6621.2019.05.011.
    [15]
    陈忠南, 易松林, 胡培磊, 等. 2012—2017年湖南省非结核分枝杆菌感染的特征分析[J]. 中国防痨杂志, 2019, 41(2): 217-221. DOI: 10.3969/j.issn.1000-6621.2019.02.017.

    CHEN ZN, YI SL, HU PL, et al. Prevalence of nontuberculosis mycobacterium infection in Hunan Province between 2012 and 2017[J]. Chin J Antituberc, 2019, 41(2): 217-221. DOI: 10.3969/j.issn.1000-6621.2019.02.017.
    [16]
    余斐, 陈晓, 嵇仲康, 等. 杭州地区2009—2014年非结核分枝杆菌流行状况分析[J]. 中国微生态学杂志, 2016, 28(7): 808-810,815. DOI: 10.13381/j.cnki.cjm.201607015.

    YU F, CHEN X, JI ZK, et al. Prevalence of Nontuberculous mycobacteriain Hangzhou during 2009-2014[J]. Chin J Microecol, 2016, 28(7): 808-810,815. DOI: 10.13381/j.cnki.cjm.201607015.
    [17]
    SMITH GS, GHIO AJ, STOUT JE, et al. Epidemiology of nontuberculous mycobacteria isolations among central North Carolina residents, 2006-2010[J]. J Infect, 2016, 72(6): 678-686. DOI: 10.1016/j.jinf.2016.03.008.
    [18]
    GEORGE IA, SANTOS CA, OLSEN MA, et al. Epidemiology and outcomes of nontuberculous mycobacterial infections in solid organ transplant recipients at a Midwestern center[J]. Transplantation, 2016, 100(5): 1073-1078. DOI: 10.1097/TP.0000000 000001123.
    [19]
    SONG Y, ZHANG L, YANG H, et al. Nontuberculous mycobacterium infection in renal transplant recipients: a systematic review[J]. Infect Dis (Lond), 2018, 50(6): 409-416. DOI: 10.1080/23744235.2017.1411604.
    [20]
    FRIEDMAN DZP, CERVERA C, HALLORAN K, et al. Non-tuberculous mycobacteria in lung transplant recipients: Prevalence, risk factors, and impact on survival and chronic lung allograft dysfunction[J]. Transpl Infect Dis, 2020, 22(2): e13229. DOI: 10.1111/tid.13229.
    [21]
    HUANG HC, WEIGT SS, DERHOVANESSIAN A, et al. Non-tuberculous mycobacterium infection after lung transplantation is associated with increased mortality[J]. J Heart Lung Transplant, 2011, 30(7): 790-798. DOI: 10.1016/j.healun.2011.02.007.
    [22]
    BALIGA S, MURPHY C, SHARON L, et al. Rapid method for detecting and differentiating Mycobacterium tuberculosis complex and non-tuberculous mycobacteria in sputum by fluorescence in situ hybridization with DNA probes[J]. Int J Infect Dis, 2018, 75: 1-7. DOI: 10.1016/j.ijid.2018.07.011.
    [23]
    KUNDURACıLAR H. Identification of mycobacteria species by molecular methods[J]. Int Wound J, 2020, 17(2): 245-250. DOI: 10.1111/iwj.13238.
    [24]
    JU CR, LIAN QY, GUAN WJ, et al. Metagenomic next-generation sequencing for diagnosing infections in lung transplant recipients: a retrospective study[J]. Transpl Int, 2022, 35: 10265. DOI: 10.3389/ti.2022.10265.
    [25]
    LIAN QY, CHEN A, ZHANG JH, et al. High-throughput next-generation sequencing for identifying pathogens during early-stage post-lung transplantation[J]. BMC Pulm Med, 2021, 21(1): 348. DOI: 10.1186/s12890-021-01723-z.
    [26]
    ZHOU X, WU H, RUAN Q, et al. Clinical evaluation of diagnosis efficacy of active mycobacterium tuberculosis complex infection via metagenomic next-generation sequencing of direct clinical samples[J]. Front Cell Infect Microbiol, 2019, 9: 351. DOI: 10.3389/fcimb.2019.00351.
    [27]
    MÜNSTER S, ZUSTIN J, DERLIN T. Atypical mycobacteriosis caused by Mycobacterium haemophilum in an immunocompromised patient: diagnosis by (18)F-FDG PET/CT[J]. Clin Nucl Med, 2013, 38(4): e194-e195. DOI: 10.1097/RLU.0b013e31826c0d51.
    [28]
    COPELAND NK, ARORA NS, FERGUSON TM. Mycobacterium haemophilum masquerading as leprosy in a renal transplant patient[J]. Case Rep Dermatol Med, 2013: 793127. DOI: 10.1155/2013/793127.
    [29]
    SOMILY AM, AL-ANAZI AR, BABAY HA, et al. Mycobacterium chelonae complex bacteremia from a post-renal transplant patient: case report and literature review[J]. Jpn J Infect Dis, 2010, 63(1): 61-64. DOI: 10.7883/yoken.63.61.
    [30]
    NIGHTINGALE SD, BYRD LT, SOUTHERN PM, et al. Incidence of mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients[J]. J Infect Dis, 1992, 165(6): 1082-1085. DOI: 10.1093/infdis/165.6.1082.
    [31]
    MORIMOTO K, NAMKOONG H, HASEGAWA N, et al. Macrolide-resistant mycobacterium avium complex lung disease: analysis of 102 consecutive cases[J]. Ann Am Thorac Soc, 2016, 13(11): 1904-1911. DOI: 10.1513/AnnalsATS.201604-246OC.
    [32]
    RICHARD M, GUTIÉRREZ AV, KREMER L. Dissecting erm(41)-Mediated Macrolide-Inducible Resistance in Mycobacterium abscessus[J]. Antimicrob Agents Chemother, 2020, 64(2): e01879-e01819. DOI: 10.1128/AAC.01879-19.
    [33]
    DE CARVALHO NFG, PAVAN F, SATO DN, et al. Genetic correlates of clarithromycin susceptibility among isolates of the Mycobacterium abscessus group and the potential clinical applicability of a PCR-based analysis of erm(41)[J]. J Antimicrob Chemother, 2018, 73(4): 862-866. DOI: 10.1093/jac/dkx476.
    [34]
    ZHANG Z, LU J, DU Y, et al. Comparison of in vitro synergistic effect between clarithromycin or azithromycin in combination with amikacin against mycobacterium intracellulare[J]. J Glob Antimicrob Resist, 2019, 18: 183-186. DOI: 10.1016/j.jgar.2019.03.017.
    [35]
    HWANG JA, KIM S, JO KW, et al. Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course[J]. Eur Respir J, 2017, 49(3): 1600537. DOI: 10.1183/13993003.00537-2016.
    [36]
    LEE G, LEE KS, MOON JW, et al. Nodular bronchiectatic Mycobacterium avium complex pulmonary disease. Natural course on serial computed tomographic scans[J]. Ann Am Thorac Soc, 2013, 10(4): 299-306. DOI: 10.1513/AnnalsATS.201303-062OC.
    [37]
    GOCHI M, TAKAYANAGI N, KANAUCHI T, et al. Retrospective study of the predictors of mortality and radiographic deterioration in 782 patients with nodular/bronchiectatic mycobacterium avium complex lung disease[J]. BMJ Open, 2015, 5(8): e008058. DOI: 10.1136/bmjopen-2015-008058.
    [38]
    HAYASHI M, TAKAYANAGI N, KANAUCHI T, et al. Prognostic factors of 634 HIV-negative patients with mycobacterium avium complex lung disease[J]. Am J Respir Crit Care Med, 2012, 185(5): 575-583. DOI: 10.1164/rccm.201107-1203OC.
    [39]
    CHOI Y, JHUN BW, KIM J, et al. Clinical characteristics and outcomes of surgically resected solitary pulmonary nodules due to nontuberculous mycobacterial infections[J]. J Clin Med, 2019, 8(11): 1898. DOI: 10.3390/jcm8111898.
    [40]
    SHULHA JA, ESCALANTE P, WILSON JW. Pharmacotherapy approaches in nontuberculous mycobacteria infections[J]. Mayo Clin Proc, 2019, 94(8): 1567-1581. DOI: 10.1016/j.mayocp.2018.12.011.
    [41]
    SWENSON C, DEL PARIGI A. Amikacin liposome inhalation suspension as a treatment option for refractory nontuberculous mycobacterial lung disease caused by mycobacterium avium complex[J]. Mayo Clin Proc, 2020, 95(1): 201-202. DOI: 10.1016/j.mayocp.2019.10.024.
    [42]
    HENKLE E, WINTHROP KL. Nontuberculous mycobacteria infections in immunosuppressed hosts[J]. Clin Chest Med, 2015, 36(1): 91-99. DOI: 10.1016/j.ccm.2014.11.002.
    [43]
    YOO JW, JO KW, KIM SH, et al. Incidence, characteristics, and treatment outcomes of mycobacterial diseases in transplant recipients[J]. Transpl Int, 2016, 29(5): 549-558. DOI: 10.1111/tri.12752.
    [44]
    JANKOVIC MAKEK M, PAVLISA G, JAKOPOVIC M, et al. Early onset of nontuberculous mycobacterial pulmonary disease contributes to the lethal outcome in lung transplant recipients: report of two cases and review of the literature[J]. Transpl Infect Dis, 2016, 18(1): 112-119. DOI: 10.1111/tid.12481.
    [45]
    KOH WJ. Nontuberculous mycobacteria-overview[M]//Tuberculosis and nontuberculous mycobacterial infections. Washington, DC, USA: ASM Press, 2017: 653-661.
    [46]
    中华医学会器官移植学分会. 器官移植术后结核病临床诊疗技术规范(2019版)[J]. 器官移植, 2019, 10(4): 359-363. DOI: 10.3969/j.issn.1674-7445.2019.04.003.

    Branch of Organ Transplantation of Chinese Medical Association. Technical specification for clinical diagnosis and treatment of tuberculosis after organ transplantation (2019 edition)[J]. Organ Transplant, 2019, 10(4): 359-363. DOI: 10.3969/j.issn.1674-7445.2019.04.003.
    [47]
    YAMADA K, SEKI Y, NAKAGAWA T, et al. Outcomes and risk factors after adjuvant surgical treatments for Mycobacterium avium complex lung disease[J]. Gen Thorac Cardiovasc Surg, 2019, 67(4): 363-369. DOI: 10.1007/s11748-018-1029-4.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (53) PDF downloads(14) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return